We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

62 hedge funds and large institutions have $106M invested in Clearside Biomedical in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,200% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 1

233% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 6

107% more funds holding

Funds holding: 30 → 62 (+32)

3.22% more ownership

Funds ownership: 0% → 3.22% (+3.2%)

23% less capital invested

Capital invested by funds: $138M → $106M (-$31.5M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
62
Holders Change
+32
Holders Change %
+106.67%
% of All Funds
1.55%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
33
Increased
20
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.6M
2
CAM
Cormorant Asset Management
Massachusetts
+$5.78M
3
BFA
BlackRock Fund Advisors
California
+$5.53M
4
O
OrbiMed
New York
+$5.02M
5
Millennium Management
Millennium Management
New York
+$4.88M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.71M
2
RSCM
Rock Springs Capital Management
Maryland
-$4.85M
3
TRCT
Tower Research Capital (TRC)
New York
-$111K
4
CS
Credit Suisse
Switzerland
-$92.6K
5
JP Morgan Chase
JP Morgan Chase
New York
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$417K +$781K +3,112 New
Goldman Sachs
27
Goldman Sachs
New York
$294K +$550K +2,192 New
BIM
28
BlackRock Investment Management
Delaware
$290K +$462K +1,841 +572%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$281K +$246K +982 +88%
Morgan Stanley
30
Morgan Stanley
New York
$260K +$485K +1,933 New
Swiss National Bank
31
Swiss National Bank
Switzerland
$252K +$472K +1,880 New
Stifel Financial
32
Stifel Financial
Missouri
$242K +$453K +1,803 New
Neuberger Berman Group
33
Neuberger Berman Group
New York
$224K +$418K +1,667 New
EMG
34
Ellington Management Group
Connecticut
$203K +$380K +1,513 New
AA
35
ALPS Advisors
Colorado
$177K +$331K +1,318 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$152K -$8.53K -34 -3%
Deutsche Bank
37
Deutsche Bank
Germany
$134K +$87.9K +350 +52%
ProShare Advisors
38
ProShare Advisors
Maryland
$133K +$250K +994 New
TCIM
39
TIAA CREF Investment Management
New York
$132K +$246K +982 New
Charles Schwab
40
Charles Schwab
California
$126K +$234K +933 New
SB
41
Suntrust Banks
Georgia
$118K – – –
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$117K +$219K +871 New
TA
43
Teachers Advisors
New York
$115K +$70K +279 +48%
CS
44
Credit Suisse
Switzerland
$114K -$92.6K -369 -30%
ARTA
45
A.R.T. Advisors
New York
$101K +$191K +760 New
TI
46
Trexquant Investment
Connecticut
$96K +$179K +713 New
Citigroup
47
Citigroup
New York
$87K +$151K +601 +1,279%
NFA
48
Nationwide Fund Advisors
Ohio
$48K +$89.6K +357 New
Wells Fargo
49
Wells Fargo
California
$35K +$66K +263 New
Barclays
50
Barclays
United Kingdom
$33K +$63.5K +253 New
1
2
3

CLSD Hedge Fund Activity: Q4 2016 in Review

62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2016, worth a combined $106M — down 23% from $138M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new CLSD positions and 1 closed out — a net gain of 32 holders — while 20 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $13.6M. The largest seller was Wellington Management Group, cutting an estimated $6.71M.

  • 62 institutional investors held Clearside Biomedical (CLSD) as of Q4 2016, up from 30 in Q3 2016.
  • Funds reported $106M of Clearside Biomedical stock for Q4 2016, down 23% quarter-over-quarter.
  • 33 funds opened new Clearside Biomedical positions in Q4 2016 and 1 closed out, a net change of +32 holders.
  • The largest Clearside Biomedical buyer in Q4 2016 was Fidelity Investments, an estimated $13.6M added.
  • The largest Clearside Biomedical seller in Q4 2016 was Wellington Management Group, an estimated $6.71M sold.

Based on aggregated 13F filings for Q4 2016.